{"id":389904,"date":"2022-01-12T00:00:00","date_gmt":"2022-01-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0057-2022-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2022\/"},"modified":"2026-03-31T10:41:10","modified_gmt":"2026-03-31T10:41:10","slug":"algoim0057-2022-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0057-2022-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2022\/","title":{"rendered":"Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2022"},"content":{"rendered":"<p>characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation\u00a0<br \/>\npredominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for\u00a0<br \/>\nIBS, and only a few drugs have secured FDA approval for IBS-D. Current prescribing among recently treated and newly diagnosed IBS-D patients?<br \/>\n\u00a0* How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?<br \/>\n\u00a0* What percentage of IBS-D patients receive drug therapy within 365 days<br \/>\n*Markets covered:* United States<br \/>\n*Key companies:* AbbVie, Salix, Sebela Pharmaceuticals<br \/>\n*Key drugs:* Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate \/ scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate<br \/>\ncharacterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation\u00a0<br \/>\npredominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for\u00a0<br \/>\nIBS, and only a few drugs have secured FDA approval for IBS-D. Current \u00a0 \u00a0prescribing among recently treated and newly diagnosed IBS-D patients?<br \/>\n\u00a0* How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?<br \/>\n\u00a0* What percentage of IBS-D patients receive drug therapy within 365 days<br \/>\n*Markets covered:* United States<br \/>\n*Key companies:* AbbVie, Salix, Sebela Pharmaceuticals<br \/>\n*Key drugs:* Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate \/ scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate<br \/>\n\u00a0<\/p>\n","protected":false},"template":"","class_list":["post-389904","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-irritable-bowel-syndrome","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389904\/revisions"}],"predecessor-version":[{"id":393029,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389904\/revisions\/393029"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}